<p>Jump Financial LLC 在第二季度購買了 West Pharmaceutical Services, Inc. (NYSE:WST - 免費報告) 的新頭寸，根據該公司最近向美國證券交易委員會提交的 13F 表格。該公司購買了 20,239 股這家醫療器械供應商的股票，價值約為 4,428,000 美元。</p>
<ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
<p>其他一些對沖基金和機構投資者也增加或減少了對該股票的持股。SYM FINANCIAL Corp 在第二季度將其在 West Pharmaceutical Services 的持股增加了 5.1%。SYM FINANCIAL Corp 目前擁有 1,027 股這家醫療器械供應商的股票，價值 225,000 美元，在此期間又購買了 50 股。Parkside Financial Bank &amp; Trust 在第二季度將其在 West Pharmaceutical Services 的持股增加了 4.0%。Parkside Financial Bank &amp; Trust 目前擁有 1,318 股這家醫療器械供應商的股票，價值 288,000 美元，在上個季度又收購了 51 股。MJP Associates Inc. ADV 在第二季度將其在 West Pharmaceutical Services 的持股增加了 2.7%。MJP Associates Inc. ADV 目前擁有 1,970 股這家醫療器械供應商的股票，價值 431,000 美元，在上個季度又收購了 52 股。Horizon Investments LLC 在第一季度將其在 West Pharmaceutical Services 的持股增加了 5.8%。Horizon Investments LLC 目前擁有 1,048 股這家醫療器械供應商的股票，價值 234,000 美元，在此期間又收購了 57 股。最後，Pallas Capital Advisors LLC 在第二季度將其在 West Pharmaceutical Services 的持股增加了 1.0%。Pallas Capital Advisors LLC 目前擁有 6,333 股這家醫療器械供應商的股票，價值 1,386,000 美元，在上個季度又購買了 62 股。機構投資者和對沖基金持有該公司 93.90% 的股票。</p>
<h2>華爾街分析師觀點</h2>
<p>幾家研究公司對 WST 發表了評論。德意志銀行設定了 West Pharmaceutical Services 股票的目標價為 345.00 美元，並在 10 月 24 日的研究報告中給予該股票 &#34;買入&#34; 評級。Wall Street Zen 在週六的報告中將 West Pharmaceutical Services 的評級從 &#34;買入&#34; 下調至 &#34;持有&#34;。Rothschild &amp; Co Redburn 在 9 月 15 日的研究報告中開始覆蓋 West Pharmaceutical Services。他們對該股票給予了 &#34;買入&#34; 評級，並設定了 311.00 美元的目標價。瑞銀集團在 10 月 24 日的研究報告中將 West Pharmaceutical Services 的目標價從 320.00 美元上調至 355.00 美元，並給予該股票 &#34;買入&#34; 評級。最後，Cowen 在 10 月 29 日的研究報告中開始覆蓋 West Pharmaceutical Services。他們對該公司給予了 &#34;買入&#34; 評級。兩位股票研究分析師對該股票給予了強烈買入評級，九位給予了買入評級，五位給予了持有評級。根據 MarketBeat.com 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 343.36 美元。</p>
<ul>
<li>今年將推動標準普爾 500 指數表現的因素是什麼？</li>
</ul>
<p><strong>查看我們最新的 West Pharmaceutical Services 股票報告</strong></p>
<h2>West Pharmaceutical Services 股票表現</h2>
<p>WST 週三開盤價為 266.02 美元。該公司的市值為 191.4 億美元，市盈率為 39.41，市盈增長比率為 4.16，貝塔值為 1.17。該公司的債務與股本比率為 0.07，流動比率為 2.87，速動比率為 2.18。West Pharmaceutical Services, Inc. 的一年低點為 187.43 美元，一年高點為 348.90 美元。該公司的 50 日移動平均價格為 273.94 美元，200 日移動平均價格為 249.16 美元。</p>
<ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
<p>West Pharmaceutical Services (NYSE:WST - 獲取免費報告) 最近在 10 月 23 日發佈了季度財報。這家醫療器械供應商報告每股收益 (EPS) 為 1.96 美元，超出市場共識預期的 1.67 美元，超出 0.29 美元。該公司季度收入為 8.046 億美元，而分析師預期為 7.8842 億美元。West Pharmaceutical Services 的股本回報率為 18.16%，淨利潤率為 16.29%。該公司的季度收入同比增長 7.7%。去年同期，該公司每股收益為 1.85 美元。West Pharmaceutical Services 已將其 2025 財年的指引設定為每股收益 7.060-7.110。研究分析師預測 West Pharmaceutical Services, Inc. 本財年將發佈 6.62 美元的每股收益。</p>
<h2>West Pharmaceutical Services 公司簡介</h2>
<p>(免費報告)</p>
<p>West Pharmaceutical Services, Inc. 設計、製造並銷售用於注射藥物和醫療保健產品的封閉和輸送系統，業務遍及美洲、歐洲、中東、非洲和亞太地區。它分為兩個部門，專有產品和合同製造產品。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 West Pharmaceutical Services</li>
<li>什麼是稀釋每股收益 (Diluted EPS)？</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年爆發</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>安海斯 - 布希收購 BeatBox 以贏得年輕飲酒者</li>
</ul>
<p><strong>想看看其他對沖基金持有的 WST 嗎？</strong> 訪問 HoldingsChannel.com 獲取 West Pharmaceutical Services, Inc. (NYSE:WST - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
<p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而西氏醫藥服務並不在名單上。</p>
<p>雖然西氏醫藥服務目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西氏醫藥服務

<p>Jump Financial LLC 在第二季度投資了 443 萬美元於西氏醫藥服務公司，購買了 20,239 股。其他機構投資者也調整了他們的持倉。分析師的評級意見不一，普遍共識為 “適度買入”，目標價格為 343.36 美元。西氏醫藥服務公司報告第三季度每股收益為 1.96 美元，超出預期，營收同比增長 7.7%。該公司的市值為 191.4 億美元，1 年股票價格區間為 187.43 美元至 348.90 美元</p>

<p>Jump Financial LLC purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 20,239 shares of the medical instruments supplier's stock, valued at approximately $4,428,000.</p>
<div class="lb-trans"><p>Jump Financial LLC 在第二季度購買了 West Pharmaceutical Services, Inc. (NYSE:WST - 免費報告) 的新頭寸，根據該公司最近向美國證券交易委員會提交的 13F 表格。該公司購買了 20,239 股這家醫療器械供應商的股票，價值約為 4,428,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. SYM FINANCIAL Corp increased its position in West Pharmaceutical Services by 5.1% in the second quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier's stock worth $225,000 after buying an additional 50 shares during the period. Parkside Financial Bank &amp; Trust grew its position in shares of West Pharmaceutical Services by 4.0% during the second quarter. Parkside Financial Bank &amp; Trust now owns 1,318 shares of the medical instruments supplier's stock worth $288,000 after acquiring an additional 51 shares during the last quarter. MJP Associates Inc. ADV grew its position in shares of West Pharmaceutical Services by 2.7% during the second quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier's stock worth $431,000 after acquiring an additional 52 shares during the last quarter. Horizon Investments LLC increased its holdings in shares of West Pharmaceutical Services by 5.8% in the 1st quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier's stock worth $234,000 after acquiring an additional 57 shares during the period. Finally, Pallas Capital Advisors LLC lifted its position in West Pharmaceutical Services by 1.0% in the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier's stock valued at $1,386,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者也增加或減少了對該股票的持股。SYM FINANCIAL Corp 在第二季度將其在 West Pharmaceutical Services 的持股增加了 5.1%。SYM FINANCIAL Corp 目前擁有 1,027 股這家醫療器械供應商的股票，價值 225,000 美元，在此期間又購買了 50 股。Parkside Financial Bank &amp; Trust 在第二季度將其在 West Pharmaceutical Services 的持股增加了 4.0%。Parkside Financial Bank &amp; Trust 目前擁有 1,318 股這家醫療器械供應商的股票，價值 288,000 美元，在上個季度又收購了 51 股。MJP Associates Inc. ADV 在第二季度將其在 West Pharmaceutical Services 的持股增加了 2.7%。MJP Associates Inc. ADV 目前擁有 1,970 股這家醫療器械供應商的股票，價值 431,000 美元，在上個季度又收購了 52 股。Horizon Investments LLC 在第一季度將其在 West Pharmaceutical Services 的持股增加了 5.8%。Horizon Investments LLC 目前擁有 1,048 股這家醫療器械供應商的股票，價值 234,000 美元，在此期間又收購了 57 股。最後，Pallas Capital Advisors LLC 在第二季度將其在 West Pharmaceutical Services 的持股增加了 1.0%。Pallas Capital Advisors LLC 目前擁有 6,333 股這家醫療器械供應商的股票，價值 1,386,000 美元，在上個季度又購買了 62 股。機構投資者和對沖基金持有該公司 93.90% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several research firms have commented on WST. Deutsche Bank Aktiengesellschaft set a $345.00 target price on shares of West Pharmaceutical Services and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 24th. Wall Street Zen lowered West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday. Rothschild &amp; Co Redburn assumed coverage on West Pharmaceutical Services in a research report on Monday, September 15th. They issued a &#34;buy&#34; rating and a $311.00 target price on the stock. UBS Group boosted their price target on West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 24th. Finally, Cowen started coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They issued a &#34;buy&#34; rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $343.36.</p>
<div class="lb-trans"><p>幾家研究公司對 WST 發表了評論。德意志銀行設定了 West Pharmaceutical Services 股票的目標價為 345.00 美元，並在 10 月 24 日的研究報告中給予該股票 &#34;買入&#34; 評級。Wall Street Zen 在週六的報告中將 West Pharmaceutical Services 的評級從 &#34;買入&#34; 下調至 &#34;持有&#34;。Rothschild &amp; Co Redburn 在 9 月 15 日的研究報告中開始覆蓋 West Pharmaceutical Services。他們對該股票給予了 &#34;買入&#34; 評級，並設定了 311.00 美元的目標價。瑞銀集團在 10 月 24 日的研究報告中將 West Pharmaceutical Services 的目標價從 320.00 美元上調至 355.00 美元，並給予該股票 &#34;買入&#34; 評級。最後，Cowen 在 10 月 29 日的研究報告中開始覆蓋 West Pharmaceutical Services。他們對該公司給予了 &#34;買入&#34; 評級。兩位股票研究分析師對該股票給予了強烈買入評級，九位給予了買入評級，五位給予了持有評級。根據 MarketBeat.com 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 343.36 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年將推動標準普爾 500 指數表現的因素是什麼？</li>
</ul>
</div><p><strong>View Our Latest Stock Report on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 West Pharmaceutical Services 股票報告</strong></p>
</div><h2>West Pharmaceutical Services Stock Performance</h2>
<div class="lb-trans"><h2>West Pharmaceutical Services 股票表現</h2>
</div><p>WST opened at $266.02 on Wednesday. The company has a market capitalization of $19.14 billion, a price-to-earnings ratio of 39.41, a price-to-earnings-growth ratio of 4.16 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $348.90. The business has a 50 day moving average price of $273.94 and a two-hundred day moving average price of $249.16.</p>
<div class="lb-trans"><p>WST 週三開盤價為 266.02 美元。該公司的市值為 191.4 億美元，市盈率為 39.41，市盈增長比率為 4.16，貝塔值為 1.17。該公司的債務與股本比率為 0.07，流動比率為 2.87，速動比率為 2.18。West Pharmaceutical Services, Inc. 的一年低點為 187.43 美元，一年高點為 348.90 美元。該公司的 50 日移動平均價格為 273.94 美元，200 日移動平均價格為 249.16 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.29. The company had revenue of $804.60 million for the quarter, compared to analysts' expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>West Pharmaceutical Services (NYSE:WST - 獲取免費報告) 最近在 10 月 23 日發佈了季度財報。這家醫療器械供應商報告每股收益 (EPS) 為 1.96 美元，超出市場共識預期的 1.67 美元，超出 0.29 美元。該公司季度收入為 8.046 億美元，而分析師預期為 7.8842 億美元。West Pharmaceutical Services 的股本回報率為 18.16%，淨利潤率為 16.29%。該公司的季度收入同比增長 7.7%。去年同期，該公司每股收益為 1.85 美元。West Pharmaceutical Services 已將其 2025 財年的指引設定為每股收益 7.060-7.110。研究分析師預測 West Pharmaceutical Services, Inc. 本財年將發佈 6.62 美元的每股收益。</p>
</div><h2>West Pharmaceutical Services Profile</h2>
<div class="lb-trans"><h2>West Pharmaceutical Services 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>West Pharmaceutical Services, Inc. 設計、製造並銷售用於注射藥物和醫療保健產品的封閉和輸送系統，業務遍及美洲、歐洲、中東、非洲和亞太地區。它分為兩個部門，專有產品和合同製造產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 West Pharmaceutical Services</li>
<li>什麼是稀釋每股收益 (Diluted EPS)？</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年爆發</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>安海斯 - 布希收購 BeatBox 以贏得年輕飲酒者</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding WST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 WST 嗎？</strong> 訪問 HoldingsChannel.com 獲取 West Pharmaceutical Services, Inc. (NYSE:WST - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而西氏醫藥服務並不在名單上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然西氏醫藥服務目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Jump Financial LLC 投資 443 萬美元於西氏醫藥服務公司（West Pharmaceutical Services, Inc.）$WST